Literature DB >> 29846974

Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study.

J R Georgakopoulos1, M Phung2, A Ighani3, K Lam3, J Yeung3,4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29846974     DOI： 10.1111/jdv.15100

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  2 in total

1.  Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study.

Authors:  Shany Sherman; Ory Zloczower; Yehonatan Noyman; Iris Amitay-Laish; Emmilia Hodak; Lev Pavlovsky
Journal:  Acta Derm Venereol       Date:  2020-12-14       Impact factor: 3.875

2.  Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population.

Authors:  Julia Berman; Victoria Furer; Mark Berman; Ofer Isakov; Devy Zisman; Amir Haddad; Ori Elkayam
Journal:  Biologics       Date:  2021-11-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.